Valens Company Inc (The) Ordinary Shares VLNCF

NEWS OUT- VLNS

[HugeMoney]

The Valens Company CEO to Participate in ATB Capital Markets' 9th Annual Institutional Investor Conference

Kelowna, B.C., January 11, 2021 – The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company” or “The Valens Company”), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to announce that Tyler Robson, CEO of The Valens Company, will participate in the ATB Capital Markets 9th Annual Institutional Investor Conference being held on January 12-14, 2021.
 
Mr. Robson is scheduled to join David Kideckel, ATB Managing Director and Senior Research Analyst, for a fireside chat titled "Cannabis 2.0... 3.0... and Beyond” on Thursday, January 14, 2021 at 9:00 am ET. Management will also host one-on-one investor meetings throughout the duration of the conference.

About The Valens Company
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing.  Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company's investor deck can be found specifically at https://thevalenscompany.com/investors/. 

For further information, please contact:

Jeff Fallows
The Valens Company

Investor Relations
[e-mail]
1 647.956.8254

KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
[e-mail]
1 212.896.1233 / 1 212.896.1203
 
Media
KCSA Strategic Communications
Anne Donohoe
[e-mail]
1 212.896.1265

[lscfa]

I think Valens moved in sympathy with Medipharm news that Q4 unit sales up 205% over Q3. Increase in stores in Ontario starting to be felt.   

[KelownaClown]

Maybe some shorts got scared and started to cover as well?

[SaltyJim]

Smart money doesn't value LABS and VLNS  same way.   But you could be right. Just think VLNS got over back on a 35% run over 2 weeks?  Next quarter is questionable but onward and upward from there!